Your Article Summary
See Latest ArticlesPulmonary neuroendocrine/carcinoid tumors
Cancer, 07/01/09
Bertino EM et al. - Although conventional cytotoxic therapy has not been reported to demonstrate much promise in this entity over the past 4 decades, newer molecular targeted agents including those that targeted angiogenesis and the mammalian target of rapamycin (mTOR) pathway have shown encouraging results in early phase trials for advanced carcinoid tumors.
Related Articles
A Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in Pulmonary Neuroendocrine Tumors
The Journal of Nuclear Medicine, 11/16/09
Relevance Score: 79%
Pulmonary Crystal-Storing Histiocytoma in a Patient Without a Lymphoproliferative Disorder
The American Journal of the Medical Sciences, 11/13/09
Relevance Score: 67%
Miscellaneous Cancers (Lung, Thyroid, Renal Cancer, Myeloma, and Neuroendocrine Tumors): Role of SPECT and PET in Imaging Bone Metastases
Seminars in Nuclear Medicine, 10/14/09
Relevance Score: 67%
Liver Metastases of Neuroendocrine Tumors: Treatment With Hepatic Transarterial Chemotherapy Using Two Therapeutic Protocols
American Journal of Roentgenology, 10/08/09
Relevance Score: 66%
Pulmonary Nodulosis and Aseptic Granulomatous Lung Disease Occurring in Patients with Rheumatoid Arthritis Receiving Tumor Necrosis Factor-alpha-Blocking Agent: A Case Series
Journal of Rheumatology, 10/07/09
Relevance Score: 66%
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer
Medical Oncology, 12/17/09
Overexpression of Phospho-eIF4E Is Associated with Survival through AKT Pathway in Non–Small Cell Lung Cancer
Clinical Cancer Research, 12/17/09
Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer
Clinical Cancer Research, 12/17/09